XELOX + bevacizumab

DRUG3 trials

Sponsors

GERCOR - Multidisciplinary Oncology Cooperative Group, Harbin Medical University, Yanqiao Zhang

Conditions

ChemotherapyColorectal CancerColorectal Cancer MetastaticColorectal Neoplasms

Phase 2

XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

Harbin Medical UniversityChemotherapy, Colorectal Neoplasms

Start: 2018-03-01End: 2020-06-01Target: 66Updated: 2018-05-01

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Not yet recruitingNCT07229846

Yanqiao ZhangColorectal Cancer

Start: 2026-02-28End: 2028-02-29Target: 30Updated: 2026-01-08

Phase 3

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruitingNCT01910610

GERCOR - Multidisciplinary Oncology Cooperative GroupColorectal Cancer Metastatic

Start: 2013-10-30End: 2024-12-31Updated: 2024-03-12

Related Papers

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.

2026-04-14

STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.

Journal of Clinical Oncology2022-06-019 citations

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.

2015-07-0417 citations

Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer : A gercor randomized open-label phase III study.

Journal of Clinical Oncology2014-05-203 citations